Our guest on this episode of "Not So Different" is Jim Van Lieshout, MBA, who joined us by phone from Colorado to discuss the many considerations that biosimilar developers must take into account when they determine how to price their products to compete in the marketplace.
In our first 2 episodes, we brought you multi-stakeholder discussions of biosimilar interchangeability and nonmedical switching.
Today, we’re changing gears and bringing you a perspective from the business side of biosimilars. Our guest on this episode of "Not So Different" is Jim Van Lieshout, MBA.
Van Lieshout is a consultant with 37 years of experience in developing market access strategies for pharmaceutical companies. Most recently, Van Lieshout worked in the Apotex family of companies, as vice president of trade and industry relations for Apobiologix. He joined us by phone from Colorado to discuss the many considerations that biosimilar developers must take into account when they determine how to price their products to compete in the marketplace.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.